Literature DB >> 20887583

Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature.

Lara A Ray1, Andia Heydari, Todd Zorick.   

Abstract

ISSUES: The development of effective treatments for alcohol use disorders represents an important public health concern. Quetiapine, a multiple receptor antagonist at 5-HT(1A) and 5-HT(2A), dopamine D(1) and D(2), histamine H(1), and adrenergic α(1) and α(2) receptors, is an atypical antipsychotic medication that has recently shown promise for the treatment of alcoholism. APPROACH: This manuscript reviews the rationale and empirical literature suggesting that quetiapine may be useful for the treatment of alcohol use disorders, including a discussion of its putative neurobiological and biobehavioural mechanisms of action. KEY
FINDINGS: The effects of quetiapine on drinking outcomes may be due to its effects on mood, anxiety and sleep, which may help alleviate protracted withdrawal symptoms and address psychiatric comorbidities often associated with alcohol use disorders. IMPLICATIONS: These findings have implications to treatment development for alcoholism and suggest that the scientific study of quetiapine for alcoholism warrants further resources and attention.
CONCLUSION: Quetiapine has advanced as a potentially promising pharmacotherapy for alcoholism. Additional research is needed to more clearly ascertain its clinical utility as a stand-alone treatment for this indication, as well as to identify patients who are more likely to respond favourably to this medication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20887583     DOI: 10.1111/j.1465-3362.2010.00185.x

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  10 in total

1.  A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.

Authors:  Raye Z Litten; Joanne B Fertig; Daniel E Falk; Megan L Ryan; Margaret E Mattson; Joseph F Collins; Cristin Murtaugh; Domenic Ciraulo; Alan I Green; Bankole Johnson; Helen Pettinati; Robert Swift; Maryam Afshar; Mary F Brunette; Nassima A-D Tiouririne; Kyle Kampman; Robert Stout
Journal:  Alcohol Clin Exp Res       Date:  2011-09-26       Impact factor: 3.455

2.  A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving.

Authors:  Lara A Ray; Pauline F Chin; Andia Heydari; Karen Miotto
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

3.  Pharmacotherapy for adolescent alcohol use disorder.

Authors:  Duncan B Clark
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

4.  Dose specific effects of olanzapine in the treatment of alcohol dependence.

Authors:  Rae A Littlewood; Eric D Claus; Pamela Arenella; Michael Bogenschutz; Hollis Karoly; Sarah W Feldstein Ewing; Angela D Bryan; Kent E Hutchison
Journal:  Psychopharmacology (Berl)       Date:  2014-10-12       Impact factor: 4.530

5.  Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN).

Authors:  Margaret E Mattson; Victoria A Albright; Joanna Yoon; Carol L Council
Journal:  Subst Abuse       Date:  2015-05-24

6.  Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.

Authors:  Yun Wang; Nanxin Huang; Hongli Li; Shubao Liu; Xianjun Chen; Shichang Yu; Nan Wu; Xiu-Wu Bian; Hai-Ying Shen; Chengren Li; Lan Xiao
Journal:  Oncotarget       Date:  2017-06-06

Review 7.  Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior?

Authors:  Sean Kim; Gayoung Lee; Eric Kim; Hyejin Jung; Jongwha Chang
Journal:  J Res Pharm Pract       Date:  2017 Jan-Mar

Review 8.  Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.

Authors:  Pascal Valentin Fischler; Michael Soyka; Erich Seifritz; Jochen Mutschler
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

9.  Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation.

Authors:  Feng Mei; Sheng Guo; Yangtao He; Linyun Wang; Hongkai Wang; Jianqin Niu; Jiming Kong; Xinmin Li; Yuzhang Wu; Lan Xiao
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

10.  MicroRNA expression profile and functional analysis reveal that miR-382 is a critical novel gene of alcohol addiction.

Authors:  Jingyuan Li; Jing Li; Xiaojun Liu; Shanshan Qin; Yanzhong Guan; Yuwei Liu; Yunhui Cheng; Xiuwen Chen; Wen Li; Shenming Wang; Ming Xiong; Eldo V Kuzhikandathil; Jiang-Hong Ye; Chunxiang Zhang
Journal:  EMBO Mol Med       Date:  2013-07-22       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.